Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Parameters influencing the efficiency of the thymidine kinase/ganciclovir strategy in human glioblastoma cell lines.

Sturtz FG, Waddell K, Shulok J, Chen X, Snodgrass HR, Platika D.

Stereotact Funct Neurosurg. 1997;68(1-4 Pt 1):252-7.

PMID:
9711725
2.

Variable efficiency of the thymidine kinase/ganciclovir system in human glioblastoma cell lines: implications for gene therapy.

Sturtz FG, Waddell K, Shulok J, Chen X, Caruso M, Sanson M, Snodgrass HR, Platika D.

Hum Gene Ther. 1997 Nov 1;8(16):1945-53.

PMID:
9382960
3.

Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma.

Rainov NG, Fels C, Droege JW, Schäfer C, Kramm CM, Chou TC.

Cancer Gene Ther. 2001 Sep;8(9):662-8.

4.
6.

Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration.

Niranjan A, Moriuchi S, Lunsford LD, Kondziolka D, Flickinger JC, Fellows W, Rajendiran S, Tamura M, Cohen JB, Glorioso JC.

Mol Ther. 2000 Aug;2(2):114-20.

7.

Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo.

Nishihara E, Nagayama Y, Mawatari F, Tanaka K, Namba H, Niwa M, Yamashita S.

Endocrinology. 1997 Nov;138(11):4577-83.

PMID:
9348181
8.

Experimental study of the RV-HSV-TK/GCV suicide gene therapy system in gastric cancer.

Tang Q, Zhang D, Wan M, Jin L.

Cancer Biother Radiopharm. 2007 Dec;22(6):755-61.

PMID:
18158766
9.

Different efficacy of in vivo herpes simplex virus thymidine kinase gene transduction and ganciclovir treatment on the inhibition of tumor growth of murine and human melanoma cells and rat glioblastoma cells.

Berenstein M, Adris S, Ledda F, Wolfmann C, Medina J, Bravo A, Mordoh J, Chernajovsky Y, Podhajcer OL.

Cancer Gene Ther. 1999 Jul-Aug;6(4):358-66.

10.

Liposomal delivery of the herpes simplex virus thymidine kinase gene in glioma: improvement of cell sensitization to ganciclovir.

Zerrouqi A, Rixe O, Ghoumari AM, Yarovoi SV, Mouawad R, Khayat D, Soubrane C.

Cancer Gene Ther. 1996 Nov-Dec;3(6):385-92.

PMID:
8988841
11.

Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.

Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS.

Cancer Res. 2001 Dec 15;61(24):8743-50.

12.

Perspectives for the gene therapy of malignant gliomas by suicide gene transfer.

Di Meco F, Benedetti S, Colombo MP, Finocchiaro G.

J Neurosurg Sci. 1997 Sep;41(3):227-34.

PMID:
9444575
14.

Limited efficacy of gene transfer in herpes simplex virus-thymidine kinase/ganciclovir gene therapy for brain tumors.

Hadaczek P, Mirek H, Berger MS, Bankiewicz K.

J Neurosurg. 2005 Feb;102(2):328-35.

PMID:
15739562
15.

[Bystander effect mediated by herpes simplex virus-thymidine kinase/ganciclovir approach on prostatic cancer cells and its regulation].

Xing Y, Lu G, Xiao Y, Zeng F, Zhang Q, Xiong P, Feng W.

Zhonghua Yi Xue Za Zhi. 2002 Nov 10;82(21):1484-7. Chinese.

PMID:
12509912
16.
17.
18.

Retroviral transfer of HSV1-TK gene into human lung cancer cell line.

Hasegawa Y, Emi N, Shimokata K.

J Mol Med (Berl). 1995 Mar;73(3):107-12. Review.

PMID:
7633946
19.
20.

Multi-log cytotoxicity of carbocyclic 2'-deoxyguanosine in HSV-TK-expressing human tumor cells.

Shewach DS, Murphy PJ, Robinson BW, Vuletich J, Boucher PD, Blobaum AL, Zerbe L, Secrist JA 3rd, Parker WB.

Hum Gene Ther. 2002 Mar 1;13(4):543-51.

Supplemental Content

Support Center